Kyverna Therapeutics, Inc.
Company Stats
- Market Cap
- $420.5M
- as of Sep 30, 2026
- Shares Outstanding
- 61.8M
- Free Float
- 50.2%
Income Statement
- Operating Income
- -$169.8M
- Net Income
- -$161.3M
- EBITDA
- -$168.0M
- Non-cash Impairment
- $600,000
Cash Flow
- Free Cash Flow
- -$153.7M
- FCF Yield
- -36.6%
- Owner FCF Yield
- -38.9%
Balance Sheet
- Cash & Equivalents
- $124.1M
Returns & Capital
- SBC, 3Y Avg
- $6.9M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$153.7M | — |
| FY2024 | — | -$116.5M | — |
| FY2023 | — | -$53.0M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 6, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges